Cargando…

Bombyx mori gloverin A2 alleviates enterotoxigenic Escherichia coli-induced inflammation and intestinal mucosa disruption

BACKGROUND: Enterotoxigenic Escherichia coli (ETEC) is one of the leading bacterial causes of intestinal inflammation and diarrhea. However, the ETEC is frequently resistant to common antibiotics. In this study, we explored the role of a novel antibacterial peptide Bombyx mori gloverin A2 (BMGlvA2)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Qian, Su, Guoqi, Wu, Aimin, Chen, Daiwen, Yu, Bing, Huang, Zhiqing, Luo, Yuheng, Mao, Xiangbing, Zheng, Ping, Yu, Jie, Luo, Junqiu, He, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878672/
https://www.ncbi.nlm.nih.gov/pubmed/31788236
http://dx.doi.org/10.1186/s13756-019-0651-y
_version_ 1783473495167991808
author Lin, Qian
Su, Guoqi
Wu, Aimin
Chen, Daiwen
Yu, Bing
Huang, Zhiqing
Luo, Yuheng
Mao, Xiangbing
Zheng, Ping
Yu, Jie
Luo, Junqiu
He, Jun
author_facet Lin, Qian
Su, Guoqi
Wu, Aimin
Chen, Daiwen
Yu, Bing
Huang, Zhiqing
Luo, Yuheng
Mao, Xiangbing
Zheng, Ping
Yu, Jie
Luo, Junqiu
He, Jun
author_sort Lin, Qian
collection PubMed
description BACKGROUND: Enterotoxigenic Escherichia coli (ETEC) is one of the leading bacterial causes of intestinal inflammation and diarrhea. However, the ETEC is frequently resistant to common antibiotics. In this study, we explored the role of a novel antibacterial peptide Bombyx mori gloverin A2 (BMGlvA2) in alleviating ETEC-induced inflammation and intestinal epithelium disruption in mice. METHODS: An ETEC-challenged mice model was used, and the ETEC-challenged mice and non-challenged mice were treated by the BMGlvA2 at different doses. RESULTS: ETEC challenge not only elevated the concentrations of serum inflammatory cytokines such as the IL-6 and TNF-α (P < 0.01), but also elevated the concentrations of serum creatinine and urea (P < 0.05). However, BMGlvA2 attenuated the inflammatory responses by decreasing the serum inflammatory cytokines and improving the metabolisms in ETEC-challenged mice, and alleviated the ETEC-induced tissue damage in spleen. Moreover, BMGlvA2 treatment significantly elevated the duodenum villus height and decreased the crypt depth in the duodenum and ileum in ETEC-challenged mice (P < 0.05). Interestingly, BMGlvA2 improved the distribution and abundance of tight-junction protein ZO1 in duodenum and ileum epithelium after ETEC-challenge. Moreover, BMGlvA2 significantly down-regulated the expression levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α) and the apoptosis-related genes (Caspase 8 and Caspase 9) in jejunal mucosa (P < 0.05) in the TETC-challenged mice. Importantly, BMGlvA2 significantly elevated the expression levels of critical genes related to mucosal barrier functions such as the mucins (MUC1 and MUC2) and glucose transporter (GLUT2) in the intestinal mucosa (P < 0.05). CONCLUSION: Our results suggested a novel function of the conventional antibacterial peptides, and the anti-bacterial and anti-inflammatory properties of BMGlvA2 may allow it a potential substitute for conventionally used antibiotics or drugs.
format Online
Article
Text
id pubmed-6878672
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68786722019-11-29 Bombyx mori gloverin A2 alleviates enterotoxigenic Escherichia coli-induced inflammation and intestinal mucosa disruption Lin, Qian Su, Guoqi Wu, Aimin Chen, Daiwen Yu, Bing Huang, Zhiqing Luo, Yuheng Mao, Xiangbing Zheng, Ping Yu, Jie Luo, Junqiu He, Jun Antimicrob Resist Infect Control Research BACKGROUND: Enterotoxigenic Escherichia coli (ETEC) is one of the leading bacterial causes of intestinal inflammation and diarrhea. However, the ETEC is frequently resistant to common antibiotics. In this study, we explored the role of a novel antibacterial peptide Bombyx mori gloverin A2 (BMGlvA2) in alleviating ETEC-induced inflammation and intestinal epithelium disruption in mice. METHODS: An ETEC-challenged mice model was used, and the ETEC-challenged mice and non-challenged mice were treated by the BMGlvA2 at different doses. RESULTS: ETEC challenge not only elevated the concentrations of serum inflammatory cytokines such as the IL-6 and TNF-α (P < 0.01), but also elevated the concentrations of serum creatinine and urea (P < 0.05). However, BMGlvA2 attenuated the inflammatory responses by decreasing the serum inflammatory cytokines and improving the metabolisms in ETEC-challenged mice, and alleviated the ETEC-induced tissue damage in spleen. Moreover, BMGlvA2 treatment significantly elevated the duodenum villus height and decreased the crypt depth in the duodenum and ileum in ETEC-challenged mice (P < 0.05). Interestingly, BMGlvA2 improved the distribution and abundance of tight-junction protein ZO1 in duodenum and ileum epithelium after ETEC-challenge. Moreover, BMGlvA2 significantly down-regulated the expression levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α) and the apoptosis-related genes (Caspase 8 and Caspase 9) in jejunal mucosa (P < 0.05) in the TETC-challenged mice. Importantly, BMGlvA2 significantly elevated the expression levels of critical genes related to mucosal barrier functions such as the mucins (MUC1 and MUC2) and glucose transporter (GLUT2) in the intestinal mucosa (P < 0.05). CONCLUSION: Our results suggested a novel function of the conventional antibacterial peptides, and the anti-bacterial and anti-inflammatory properties of BMGlvA2 may allow it a potential substitute for conventionally used antibiotics or drugs. BioMed Central 2019-11-26 /pmc/articles/PMC6878672/ /pubmed/31788236 http://dx.doi.org/10.1186/s13756-019-0651-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lin, Qian
Su, Guoqi
Wu, Aimin
Chen, Daiwen
Yu, Bing
Huang, Zhiqing
Luo, Yuheng
Mao, Xiangbing
Zheng, Ping
Yu, Jie
Luo, Junqiu
He, Jun
Bombyx mori gloverin A2 alleviates enterotoxigenic Escherichia coli-induced inflammation and intestinal mucosa disruption
title Bombyx mori gloverin A2 alleviates enterotoxigenic Escherichia coli-induced inflammation and intestinal mucosa disruption
title_full Bombyx mori gloverin A2 alleviates enterotoxigenic Escherichia coli-induced inflammation and intestinal mucosa disruption
title_fullStr Bombyx mori gloverin A2 alleviates enterotoxigenic Escherichia coli-induced inflammation and intestinal mucosa disruption
title_full_unstemmed Bombyx mori gloverin A2 alleviates enterotoxigenic Escherichia coli-induced inflammation and intestinal mucosa disruption
title_short Bombyx mori gloverin A2 alleviates enterotoxigenic Escherichia coli-induced inflammation and intestinal mucosa disruption
title_sort bombyx mori gloverin a2 alleviates enterotoxigenic escherichia coli-induced inflammation and intestinal mucosa disruption
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878672/
https://www.ncbi.nlm.nih.gov/pubmed/31788236
http://dx.doi.org/10.1186/s13756-019-0651-y
work_keys_str_mv AT linqian bombyxmorigloverina2alleviatesenterotoxigenicescherichiacoliinducedinflammationandintestinalmucosadisruption
AT suguoqi bombyxmorigloverina2alleviatesenterotoxigenicescherichiacoliinducedinflammationandintestinalmucosadisruption
AT wuaimin bombyxmorigloverina2alleviatesenterotoxigenicescherichiacoliinducedinflammationandintestinalmucosadisruption
AT chendaiwen bombyxmorigloverina2alleviatesenterotoxigenicescherichiacoliinducedinflammationandintestinalmucosadisruption
AT yubing bombyxmorigloverina2alleviatesenterotoxigenicescherichiacoliinducedinflammationandintestinalmucosadisruption
AT huangzhiqing bombyxmorigloverina2alleviatesenterotoxigenicescherichiacoliinducedinflammationandintestinalmucosadisruption
AT luoyuheng bombyxmorigloverina2alleviatesenterotoxigenicescherichiacoliinducedinflammationandintestinalmucosadisruption
AT maoxiangbing bombyxmorigloverina2alleviatesenterotoxigenicescherichiacoliinducedinflammationandintestinalmucosadisruption
AT zhengping bombyxmorigloverina2alleviatesenterotoxigenicescherichiacoliinducedinflammationandintestinalmucosadisruption
AT yujie bombyxmorigloverina2alleviatesenterotoxigenicescherichiacoliinducedinflammationandintestinalmucosadisruption
AT luojunqiu bombyxmorigloverina2alleviatesenterotoxigenicescherichiacoliinducedinflammationandintestinalmucosadisruption
AT hejun bombyxmorigloverina2alleviatesenterotoxigenicescherichiacoliinducedinflammationandintestinalmucosadisruption